Arek Z. Dudek

Investigator
Medical oncologist and hematologist
HealthPartners Research Foundation
United States of America

Scientist Haematology
Biography

Arek Z. Dudek is a Investigator, Metro-Minnesota Community Oncology Research Consortiumand Medical oncologist and hematologist, he has completed his MD, Medical University of Warsaw, Poland; internal medicine residency, Pinnacle Health Hospitals, Harrisburg, PA; fellowship in hematology and oncology, University of Minnesota.Dr. Dudek has been published more than 100 times in peer-reviewed medical journals for his work in lung cancer, melanoma and kidney cancer. In addition, he has written several editorials and book chapters on topics such as tumor biology and targeted cancer therapies. He serves as a research and clinical mentor to graduate students, junior faculty and clinicians.

Research Intrest

Dr. Dudek discovered his calling to become a medical oncologist very early in medical school. He found cancer to be one of the most challenging human diseases, requiring the physician to have broad knowledge of all other medical disciplines and an understanding of cellular and molecular biology. The need for development of better therapies for cancer has led Dr. Dudek to look for novel cancer therapeutics and provide them to his patients who participate in cancer clinical trials in the early-phase clinical trials program at Regions Hospital.

List of Publications
Phase II study of panobinostat and bortezomib in patients with pancreatic cancer progressing on gemcitabine-based therapy.
Phase II study of dasatinib in patients with previously treated malignant mesothelioma (cancer and leukemia group B 30601): a brief report.
Pathway-based pharmacogenomics of gemcitabine pharmacokinetics in patients with solid tumors.
Tumor angiogenesis 2012.
Phase II study of biweekly carboplatin, gemcitabine, and bevacizumab as first-line treatment in patients with stage IIIB/IV NSCLC.
Randomized phase II study of IL-2 with or without an allogeneic large multivalent immunogen vaccine for the treatment of stage IV melanoma.
Mechanisms limiting distribution of the threonine-protein kinase B-RaF(V600E) inhibitor dabrafenib to the brain: implications for the treatment of melanoma brain metastases.
Brain metastases from renal cell carcinoma in the era of tyrosine kinase inhibitors.
Capecitabine to reduce nonmelanoma skin carcinoma burden in solid organ transplant recipients.
Dystonia in a patient with melanoma metastatic to the brain treated with high-dose interleukin-2, radiation therapy, and levetiracetam.
Profound impairment of adaptive immune responses by alkylating chemotherapy.
Phase II study of topotecan and bevacizumab in advanced, refractory non--small-cell lung cancer.
Alkylating chemotherapy may exert a uniquely deleterious effect upon neo-antigen-targeting anticancer vaccination.
SLC28A3 genotype and gemcitabine rate of infusion affect dFdCTP metabolite disposition in patients with solid tumours.
Phase I Study of Pazopanib and Ixabepilone in Patients With Solid Tumors.
Impact of BRAF mutation and BRAF inhibition on melanoma brain metastases.
Prognostic significance of microscopic tumor burden in sentinel lymph node in patients with cutaneous melanoma.
Chondroitin sulfate proteoglycan-4 does not protect melanoma cells during inhibition of PI3K and mTOR pathways.
Prolonged survival with personalized immunotherapy (AGS-003) in combination with sunitinib in unfavorable risk metastatic RCC (mRCC).
Phase II study combining personalized dendritic cell (DC)-based therapy, AGS-003, with sunitinib in metastatic renal cell carcinoma (mRCC).